In this episode, Chris Patil speaks with Dr. Mehmood Khan, CEO of Hevolution Foundation, about the organization’s mission to extend healthy human lifespan and better understand the aging process. Dr. Khan discusses Hevolution’s unique approach to funding global scientific discovery and investing in private companies dedicated to advancing aging science. He shares insights into the challenges and opportunities in the field of longevity research, the importance of global collaboration, and the potential impact of extending healthspan on societies worldwide.
The Finer Details:
Hevolution Foundation’s origin and mission
The importance of aging research in the context of global challenges
Hevolution’s collaborative approach and funding strategies
Challenges in translating aging research into accessible interventions
The need for validated biomarkers in aging research
Global perspectives on aging, including challenges in developing countries
The importance of policy engagement and public awareness in advancing the field
Here is a presentation by William Greene, who leads the Investment (commercial) side of the Revolution Foundation (they have a non-profit / grants side also). In it he covers Hevolution’s Vision and Investment Strategy.
They aim to revolutionize healthspan science by:
• Funding cutting-edge research
• Supporting biogerontology investigators
• Translating discoveries into therapeutics
• Launching VC for longevity biotech
They really focused in on ‘healthspan’, this seems like a term that has tested best among the general public. But barely anyone searches for healthspan vs. other terms like longevity?
Yes - I think you’re right on both accounts. I think the hope is that because “healthspan” resonates with people better than other terms, that the science will appeal more to mainstream medical professionals (over time) and so there is greater likelihood of adoption and promotion by healthcare professionals… so more acceptance of the research and putting it into practice, and greater ultimate adoption of the resulting therapeutics.
